SAN FRANCISCO—Initiating statin therapy after radical prostatectomy (RP) may decrease the risk of biochemical recurrence of prostate cancer, new data suggest.

A greater than twofold increased risk observed in men with the highest versus the lowest levels.

It is associated with better improvements in insulin sensitivity and beta-cell function, study shows.

NEW YORK—New findings suggest that electronic health records (EHR) with special features for managing hypertension may be highly beneficial in improving BP control.

Doctors may be able to head off ESRD and CVD by treating pre-diabetes and pre-hypertension sooner.

NEW YORK—An investigational triple regimen of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) may result in significantly greater mean reductions in BP compared with a combination of any two of these drugs in patients with moderate to severe hypertension, new data show.

CHICAGO—A novel drug called eribulin may be effective for advanced urothelial cancer (UC), even in patients with prior adjuvant or neoadjuvant chemotherapy, according to new data presented at the American Society of Clinical Oncology annual meeting.

CHICAGO—DNA blood tests under development may provide a more accurate way to detect prostate and breast cancer, according to findings presented at the American Society of Clinical Oncology annual meeting.

CHICAGO—Testicular cancer survivors treated with chemotherapy and radiotherapy are at increased risk for cardiovascular disease (CVD), researchers reported at the American Society of Clinical Oncology annual meeting. These patients also are at higher risk for hypertension and diabetes.

Recurrence rates after percutaneous embolization are similar to those of surgery, researcher says.